Fig. 2: Comparative characteristics of the SARS-CoV-2 RBD-binding human monoclonal antibodies. | Cell Discovery

Fig. 2: Comparative characteristics of the SARS-CoV-2 RBD-binding human monoclonal antibodies.

From: Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern

Fig. 2: Comparative characteristics of the SARS-CoV-2 RBD-binding human monoclonal antibodies.

Heat maps are shown for monoclonal antibody blocking of ACE2/RBD interaction (%), staining of cell-surface expressed SARS-CoV-2 Spike (%), neutralization of Spike-pseudotyped lentiviral particles (IC50) or authentic SARS-CoV-2 virus (IC100), KD for the interaction with recombinant RBD (BLI measurements), autoreactivity (fold MFI increase above background), and SHM rate (number of nucleotide substitutions). Antibodies are grouped and ordered by neutralization potency and were either obtained in this study (iB0-26) or reported earlier (10933, REGN10933; 10987, REGN10987; 2504, COV2-2504; 2015, COVA2-15)5,8,11. All numerical values can be found in Supplementary Table S2.

Back to article page